Evidence map›Paper›PMID 42495131›Full record

ArticleFrontiers in microbiology2026

Emergence of ST1076 as a dominant high-risk clone carrying

Xiaolan Shou, Xiangchen Li, Hongyin Yang, Xiaofan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaolan Shou *Department of Clinical Laboratory, Deqing People's Hospital (Deqing Campus, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University), Deqing, Zhejiang, China.
Xiangchen Li *Jiaxing Key Laboratory of Clinical Laboratory Diagnostics and Translational Research, Affiliated Hospital of Jiaxing University, Jiaxing, China.
Hongyin Yang *Department of Clinical Laboratory, Feicheng Hospital of Traditional Chinese Medicine, Taian, Shandong, China.
Xiaofan ZhangDepartment of Clinical Laboratory, Feicheng Hospital of Traditional Chinese Medicine, Taian, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem-resistant Methods: We analyzed 100 non-duplicate CRPA clinical isolates collected from June 2020 to December 2024 in Deqing, Zhejiang Province, China. Antimicrobial susceptibility was determined by automated systems, and molecular characterization was performed via whole-genome sequencing, multilocus sequence typing (MLST), core-genome single nucleotide polymorphism (SNP) phylogeny, resistance and virulence gene profiling, and phylogeographic analysis. Results: The observed resistance rates were 95% for imipenem and 91% for meropenem. Carbapenemase-producing isolates comprised 44% (44/100), with Conclusion: This study reveals the emergence and sustained ICU-associated transmission of

Indexed as

carbapenem-resistant Pseudomonas aeruginosaceftazidime/avibactamKPC-2molecular epidemiologynosocomial transmissionST1076

Identifiers

PMID42495131
PMCPMC13391571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.